It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Amid the Coronavirus Disease 2019 pandemic, we aimed to demonstrate the accuracy of the fingertip whole blood sampling test (FWT) in measuring the antibody titer and uncovering its dynamics shortly after booster vaccination. Mokobio SARS-CoV-2 IgM & IgG Quantum Dot immunoassay (Mokobio Biotechnology R&D Center Inc., MD, USA) was used as a point-of-care FWT in 226 health care workers (HCWs) who had received two doses of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) at least 8 months prior. Each participant tested their antibody titers before and after the third-dose booster up to 14-days. The effect of the booster was observed as early as the fourth day after vaccination, which exceeded the detection limit (> 30,000 U/mL) by 2.3% on the fifth day, 12.2% on the sixth day, and 22.5% after the seventh day. Significant positive correlations were observed between the pre- and post-vaccination (the seventh and eighth days) antibody titers (correlation coefficient, 0.405; p < 0.001). FWT is useful for examining antibody titers as a point-of-care test. Rapid response of antibody titer started as early as the fourth day post-vaccination, while the presence of weak responders to BNT162b2 vaccine was indicated.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of General Medicine, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472)
2 Okayama University Hospital, Clinical Laboratory, Okayama, Japan (GRID:grid.412342.2) (ISNI:0000 0004 0631 9477)
3 Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Emergency, Critical Care, and Disaster Medicine, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472)
4 Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Epidemiology, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472)
5 Okayama University, Office of Innovative Medicine, Organization for Research Strategy and Development, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472); Max Planck Institute for Heart and Lung Research, Laboratory for Cell Polarity and Organogenesis, Bad Nauheim, Germany (GRID:grid.418032.c) (ISNI:0000 0004 0491 220X)
6 Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Departments of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472)
7 Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Hematology and Oncology, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472)
8 Yokokura Hospital, Fukuoka, Japan (GRID:grid.261356.5)
9 Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of General Medicine, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472); Okayama University Hospital, Clinical Laboratory, Okayama, Japan (GRID:grid.412342.2) (ISNI:0000 0004 0631 9477)